Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus lenvatinib in previously treated patients with select solid tumors; results on efficacy and safety have been posted.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Gastric Cancer
• Glioblastoma
• Ovarian Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-11-17